| 39.12 -3.38 (-7.95%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 52.4 | 1-year : | 61.21 |
| Resists | First : | 44.86 | Second : | 52.4 |
| Pivot price | 41.93 |
|||
| Supports | First : | 36.27  |
Second : | 30.96 |
| MAs | MA(5) : | 41.65 |
MA(20) : | 40.76 |
| MA(100) : | 38.56 |
MA(250) : | 35.47 |
|
| MACD | MACD : | 1.4 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 59.4 |
D(3) : | 66.9 |
| RSI | RSI(14): 47.9 |
|||
| 52-week | High : | 56.04 | Low : | 19.06 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VERA ] has closed below the lower bollinger band by 10.3%. Bollinger Bands are 33.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 42.34 - 42.58 | 42.58 - 42.84 |
| Low: | 38.45 - 38.7 | 38.7 - 38.98 |
| Close: | 38.65 - 39.08 | 39.08 - 39.56 |
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Thu, 16 Jul 2026
Enterprise value to revenue forward of Vera Therapeutics, Inc. – NASDAQ:VERA - TradingView
Sat, 11 Jul 2026
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch - Yahoo Finance
Thu, 09 Jul 2026
Vera Therapeutics Announces Appointment of Nancy Boman as - GlobeNewswire
Wed, 08 Jul 2026
US FDA approves Vera's kidney disease drug - Reuters
Tue, 07 Jul 2026
Vera Therapeutics wins first FDA approval with kidney disease drug - The Business Journals
Tue, 07 Jul 2026
FDA approves Vera Therapeutics kidney disease treatment - STAT
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 52 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 110.5 (%) |
| Shares Short | 13,520 (K) |
| Shares Short P.Month | 10,830 (K) |
| EPS | -5.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39 % |
| Return on Equity (ttm) | -71.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -5.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -293 (M) |
| Levered Free Cash Flow | -179 (M) |
| PE Ratio | -7.07 |
| PEG Ratio | 0 |
| Price to Book value | 5.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -9.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|